Monoamine oxidase inhibition for tobacco pharmacotherapy.
Tobacco addiction is the most significant preventable cause of morbidity and mortality in the Western world, with >430,000 deaths annually from tobacco-related diseases being reported in the United States. Although effective treatments are available for cessation of smoking (e.g., nicotine replacement therapies, sustained-release bupropion and varenicline), they do not work for all smokers. Therefore the development of more effective medications for treating tobacco dependence, based on novel mechanisms, is a high priority. This article reviews the links between smoking and monoamine oxidase (MAO) inhibition, which could lead to the development of novel pharmacotherapies to treat tobacco dependence.
George
T P
TP
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. tony.george@utoronto.ca
Weinberger
A H
AH
D002986:Clinical Trials as Topic; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D012907:Smoking / Q000188:drug therapy*; D016540:Smoking Cessation / Q000379:methods*; D014029:Tobacco Use Disorder / Q000188:drug therapy* / Q000201:enzymology
D007527:Isoenzymes; D008996:Monoamine Oxidase Inhibitors